Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Alexium International Group is a specialty chemicals company focused on flame retardant and moisture management technologies, primarily serving defense, workwear, and technical textile markets. The company operates with minimal revenue scale (~$0M TTM), severe operating losses (-131% margin), and extreme financial distress indicated by negative equity and negative book value, suggesting a pre-revenue or restructuring stage business model.
Alexium develops and commercializes surface treatment technologies that modify textile properties without altering fabric characteristics. The business model appears to rely on selling chemical formulations or treatment services to textile manufacturers and military contractors. With 42% gross margin but -131% operating margin, the company faces extreme operational inefficiency, suggesting high R&D/SG&A costs relative to minimal commercial traction. The negative equity (-6.33 D/E ratio) and 976% ROE (distorted by negative equity base) indicate the company has burned through shareholder capital and likely requires recapitalization or asset sales.
Announcements of commercial contracts with defense contractors or major textile manufacturers (critical for validating technology)
Regulatory approvals or certifications for flame retardant formulations in key markets (EU, US military specifications)
Capital raises, debt restructuring, or going-concern warnings given extreme cash burn and negative equity
Strategic partnerships or acquisition interest from larger specialty chemical players (potential exit scenario)
Quarterly cash burn rate and runway to insolvency given negative operating cash flow
Regulatory risk in flame retardant chemicals - increasing scrutiny of PFAS and halogenated compounds could require reformulation or limit market access if Alexium's technologies fall under regulatory restrictions
Technology obsolescence risk - larger specialty chemical companies (Huntsman, Archroma) have greater R&D resources to develop competing textile treatment technologies
Market adoption risk - textile manufacturers face switching costs and require extensive testing/certification, creating long sales cycles that may exceed the company's financial runway
Competition from established specialty chemical giants (Huntsman, Clariant, Rudolf Group) with existing customer relationships, broader product portfolios, and financial resources to undercut pricing
Alternative flame retardant technologies including inherently flame-resistant fibers (aramids, modacrylic) that eliminate need for chemical treatments
Customer vertical integration risk - large textile manufacturers may develop proprietary treatment technologies in-house rather than rely on external suppliers
Going concern risk - negative equity of -$19.4 price/book and -131% operating margin indicate the company is burning through capital faster than it can generate revenue, creating imminent insolvency risk without additional financing
Equity dilution risk - any capital raise at current distressed valuation would be highly dilutive to existing shareholders, potentially triggering reverse splits or delisting
Liquidity crisis risk - 1.56x current ratio provides minimal cushion, and negative operating cash flow suggests the company may exhaust working capital within quarters without revenue acceleration or cost restructuring
moderate - Defense spending (a key end market) is relatively stable and driven by geopolitical factors rather than GDP cycles. However, commercial textile demand for workwear and technical fabrics correlates with industrial activity and construction employment. At current pre-revenue scale, company-specific execution risk far outweighs macro sensitivity.
High sensitivity through financing costs and equity valuation. Rising rates increase the cost of capital for cash-burning development-stage companies, making equity financing more dilutive and reducing investor appetite for speculative, unprofitable businesses. The company's ability to secure additional funding at reasonable terms deteriorates as rates rise, creating existential risk given negative cash flow.
Critical - With negative equity and severe cash burn, the company likely lacks access to traditional debt markets and depends entirely on equity financing or asset-backed lending. Tightening credit conditions would force more dilutive equity raises or asset sales. The negative D/E ratio suggests liabilities exceed assets, indicating potential insolvency risk if unable to secure additional capital.
Speculative/turnaround investors - The extreme financial distress, negative equity, and pre-revenue status attract only high-risk tolerance investors betting on technology validation, strategic acquisition, or restructuring upside. This is not suitable for value, income, or conservative growth investors. The profile resembles a venture-stage bet within public markets.
high - Micro-cap specialty chemical companies with minimal revenue, negative equity, and binary outcomes (commercial success vs. insolvency) exhibit extreme volatility. Any contract announcement, financing event, or going-concern warning would trigger double-digit percentage moves. Illiquidity amplifies volatility given likely minimal trading volume.